Company news
Ensysce Biosciences, Inc. news in 2024
Ensysce Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.
Ensysce Biosciences Regains Full Compliance with Nasdaq
December 22, 2024
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
December 9, 2024
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
December 3, 2024
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
December 2, 2024
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
November 25, 2024
Ensysce Biosciences Reports Third Quarter 2024 Financial Results
November 11, 2024
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
November 6, 2024
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
October 7, 2024
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
October 1, 2024
Ensysce Biosciences Receives Notice from Nasdaq
September 26, 2024
Ensysce Biosciences Presenting at Upcoming Meetings
September 23, 2024
Ensysce Biosciences Submits Phase 3 Protocol to the FDA
September 18, 2024
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
September 12, 2024
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants
August 28, 2024
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection
August 26, 2024
Ensysce Biosciences Announces IRB Approval for Key MPAR Study
August 26, 2024
Ensysce Biosciences Reports Second Quarter 2024 Financial Results
August 13, 2024
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium
August 7, 2024
Ensysce Biosciences Provides Mid-Year 2024 Update
July 22, 2024
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
July 8, 2024
Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
June 26, 2024
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
June 24, 2024
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
June 5, 2024
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
June 2, 2024
Ensysce Biosciences Regains Compliance with Nasdaq
May 27, 2024
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
May 19, 2024
Ensysce Biosciences Reports First Quarter 2024 Financial Results
May 12, 2024
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
April 24, 2024
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
April 18, 2024
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
April 8, 2024
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
February 20, 2024
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
February 14, 2024
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
February 12, 2024
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
February 5, 2024
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
January 30, 2024
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
January 24, 2024
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
January 22, 2024
Ensysce Biosciences Issues 2024 Shareholder Letter
January 7, 2024